Disc Medicine (IRON) Accounts Payables (2020 - 2026)
Disc Medicine (IRON) reported Accounts Payables of $11.8 million for Q1 2026, up 75.43% year-over-year from $6.7 million in Q1 2025, and up 30.39% on a QoQ basis from $9.0 million in Q4 2025.
Disc Medicine (IRON) has 7 years of Accounts Payables data on file, last reported at $11.8 million in Q1 2026.
- Quarterly Accounts Payables rose 75.43% year-over-year to $11.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.8 million (up 75.43% YoY) and the FY2025 annual result came in at $9.0 million, up 13.46% from the prior year.
- Accounts Payables rose to $11.8 million in Q1 2026 per IRON's latest filing, from $9.0 million in the prior quarter.
- Across five years, Accounts Payables topped out at $16.2 million in Q4 2022 and bottomed at $1.1 million in Q3 2022.
- The 5-year median for Accounts Payables is $6.4 million (2025), against an average of $7.0 million.
- The widest annual swing landed in 2023, when Accounts Payables soared 645.92%; it then tumbled 58.18% in 2024.
- Tracing IRON's Accounts Payables over 5 years: stood at $16.2 million in 2022, then decreased by 21.86% to $12.6 million in 2023, then tumbled by 37.07% to $7.9 million in 2024, then gained by 13.46% to $9.0 million in 2025, then soared by 30.39% to $11.8 million in 2026.
- Per Business Quant, the three latest IRON Accounts Payables figures stand at $11.8 million (Q1 2026), $9.0 million (Q4 2025), and $7.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | 11.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.76 Mn |
| Dec 31, 2025 | 9.02 Mn |
| Sep 30, 2025 | 7.27 Mn |
| Jun 30, 2025 | 6.35 Mn |
| Mar 31, 2025 | 6.70 Mn |
| Dec 31, 2024 | 7.95 Mn |
| Sep 30, 2024 | 3.55 Mn |
| Jun 30, 2024 | 4.75 Mn |
| Mar 31, 2024 | 5.27 Mn |
| Dec 31, 2023 | 12.63 Mn |
| Sep 30, 2023 | 8.50 Mn |
| Jun 30, 2023 | 5.21 Mn |
| Mar 31, 2023 | 5.64 Mn |
| Dec 31, 2022 | 16.16 Mn |
| Sep 30, 2022 | 1.14 Mn |
| Jun 30, 2022 | 1.62 Mn |
| Mar 31, 2022 | 5.11 Mn |
| Dec 31, 2021 | 2.56 Mn |
| Sep 30, 2021 | 939,000.00 |
| Jun 30, 2021 | 1.49 Mn |
| Mar 31, 2021 | 3.56 Mn |
| Dec 31, 2020 | 2.38 Mn |
| Sep 30, 2020 | 40,489.00 |